REYATAZ DIN 02294176
Status: Cancelled Post Market
Holder: BRISTOL-MYERS SQUIBB CANADA
Molecule: ATAZANAVIR (ATAZANAVIR SULFATE)
Available to quote
Health Canada record
| Active ingredient(s) | ATAZANAVIR (ATAZANAVIR SULFATE) 300 MG |
|---|---|
| Dosage form | Capsule |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J05AE08 ATAZANAVIR |
| Original market date | 31-May-2007 |
| Current status date | 30-Jul-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Bristol-Myers Squibb Canada — licence 100100, currently licensed, last inspection rating C (2026-03-18).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ATAZANAVIR (ATAZANAVIR SULFATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02479249 | APO-ATAZANAVIR | APOTEX INC | Capsule | ATAZANAVIR (ATAZANAVIR SULFATE) 150 MG | Approved |
| 02479265 | APO-ATAZANAVIR | APOTEX INC | Capsule | ATAZANAVIR (ATAZANAVIR SULFATE) 300 MG | Approved |
| 02479257 | APO-ATAZANAVIR | APOTEX INC | Capsule | ATAZANAVIR (ATAZANAVIR SULFATE) 200 MG | Approved |
| 02456893 | MYLAN-ATAZANAVIR | MYLAN PHARMACEUTICALS ULC | Capsule | ATAZANAVIR (ATAZANAVIR SULFATE) 300 MG | Marketed |
| 02456877 | MYLAN-ATAZANAVIR | MYLAN PHARMACEUTICALS ULC | Capsule | ATAZANAVIR (ATAZANAVIR SULFATE) 150 MG | Marketed |
| 02456885 | MYLAN-ATAZANAVIR | MYLAN PHARMACEUTICALS ULC | Capsule | ATAZANAVIR (ATAZANAVIR SULFATE) 200 MG | Marketed |
| 02443791 | TEVA-ATAZANAVIR | TEVA CANADA LIMITED | Capsule | ATAZANAVIR (ATAZANAVIR SULFATE) 150 MG | Marketed |
| 02443813 | TEVA-ATAZANAVIR | TEVA CANADA LIMITED | Capsule | ATAZANAVIR (ATAZANAVIR SULFATE) 200 MG | Marketed |
| 02443821 | TEVA-ATAZANAVIR | TEVA CANADA LIMITED | Capsule | ATAZANAVIR (ATAZANAVIR SULFATE) 300 MG | Marketed |
| 02446731 | EVOTAZ | BRISTOL-MYERS SQUIBB CANADA | Tablet | ATAZANAVIR (ATAZANAVIR SULFATE) 300 MG; COBICISTAT 150 MG | Cancelled Post Market |
| 02513129 | JAMP ATAZANAVIR | JAMP PHARMA CORPORATION | Capsule | ATAZANAVIR (ATAZANAVIR SULFATE) 300 MG | Dormant |
| 02513102 | JAMP ATAZANAVIR | JAMP PHARMA CORPORATION | Capsule | ATAZANAVIR (ATAZANAVIR SULFATE) 150 MG | Dormant |
| 02513110 | JAMP ATAZANAVIR | JAMP PHARMA CORPORATION | Capsule | ATAZANAVIR (ATAZANAVIR SULFATE) 200 MG | Dormant |
| 02248609 | REYATAZ | BRISTOL-MYERS SQUIBB CANADA | Capsule | ATAZANAVIR (ATAZANAVIR SULFATE) 100 MG | Cancelled Pre Market |
| 02248611 | REYATAZ | BRISTOL-MYERS SQUIBB CANADA | Capsule | ATAZANAVIR (ATAZANAVIR SULFATE) 200 MG | Cancelled Post Market |
| 02248610 | REYATAZ | BRISTOL-MYERS SQUIBB CANADA | Capsule | ATAZANAVIR (ATAZANAVIR SULFATE) 150 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 8758 | 2007-05-02 | Supplement to a New Drug Submission (SNDS) | NEW STRENGTH - 300MG CAPSULE |